Please assess the completion status of the following clinical trial:

Trial Title: The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Literacy in one of the study languages (Thai, Xhosa, and/or English)~* Able to provide written informed consent~* Able to provide weekly telephonic updates~* Within 70 days of enrollment:~  1. Serum creatinine less than or equal to the upper limit of normal (ULN) and calculated creatinine clearance of at least 70 mL/min by the Cockcroft-Gault formula. More information on this criterion can be found in the protocol.~ 2. Serum phosphate greater than or equal to the lower limit of normal (LLN)~ 3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 2 times ULN~ 4. Hemoglobin greater than 10 g/dL~ 5. Hepatitis B surface antigen (HBsAg)-negative~ 6. Willing and able to provide adequate locator information~Inclusion Criteria for MSM/TGW:~* Male at birth~* Reporting anal intercourse and/or receptive neovaginal intercourse with at least one man or transgender woman in the past 6 months~* One or more of the following risk factors for HIV acquisition in the past 6 months according to self-report: sexual intercourse with more than one man or transgender woman; history of an acute sexually transmitted infection (STI); sex in exchange for money, goods, or favors; condomless intercourse (oral, anal, vaginal, or neovaginal) with a partner known to be HIV-infected or of unknown HIV infection status according to self report~Inclusion Criteria for Women Who Have Sex With Men (WSM):~* Female at birth or self identify as female~* Not pregnant or breastfeeding~* Not able to or not intending to become pregnant during the next year~* If able to become pregnant, self reported use of an effective method of contraception at Enrollment, and intending to use an effective method for the next 34 weeks~* One or more of the following risk factors for HIV acquisition in the past 6 months according to self report: sexual intercourse with more than one man; history of an acute STI; sex in exchange for money, goods or favors; condomless intercourse (oral, anal, or vaginal) with a partner known to be HIV-infected or of unknown HIV infection status~Exclusion Criteria:~* Proteinuria 2+ or greater at screening~* Glucosuria 2+ or greater at screening~* Serious and active medical or mental illness~* One or both HIV rapid tests is reactive at screening or enrollment, regardless of subsequent HIV diagnostic test results~* Signs or symptoms suggestive of acute HIV infection~* Use of hypoglycemic agents for diabetes or agents with known nephrotoxic potential~* Use of ARV therapy (e.g., for post-exposure prophylaxis \[PEP\] or PrEP) in the 90 days prior to study entry~* Serum phosphate level below site laboratory LLN~* Current participation (or participation within 3 months of screening) in any HIV prevention study~* Previous or current participation in the active arm of an HIV vaccine trial~* Acute or chronic hepatitis B (HBV) infection (refers to chronic active HBV infection evidenced by a positive test for hepatitis B surface antigen (HBsAg)~* Presence of a psychological or social condition or an addictive disorder that would preclude compliance with the protocol~* Any other reason or condition that in the opinion of the investigator would interfere with participation, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Daily dosing (Type: ACTIVE_COMPARATOR): Participants will receive oral FTC/TDF daily.
- Time-driven dosing (Type: EXPERIMENTAL): Participants will receive oral FTC/TDF twice weekly with a post-exposure dose.
- Event-driven dosing (Type: EXPERIMENTAL): Participants will receive oral FTC/TDF before and after a potential exposure to HIV infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).